"Gene Products, tat" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Trans-acting transcription factors produced by retroviruses such as HIV. They are nuclear proteins whose expression is required for viral replication. The tat protein stimulates LONG TERMINAL REPEAT-driven RNA synthesis for both viral regulatory and viral structural proteins. tat stands for trans-activation of transcription.
| Descriptor ID |
D015696
|
| MeSH Number(s) |
D12.776.260.755.199 D12.776.930.900.199 D12.776.964.925.984.400
|
| Concept/Terms |
Gene Products, tat- Gene Products, tat
- tat Gene Products
- tat Protein
- Gene Product, tat
- tat Gene Product
|
Below are MeSH descriptors whose meaning is more general than "Gene Products, tat".
Below are MeSH descriptors whose meaning is more specific than "Gene Products, tat".
This graph shows the total number of publications written about "Gene Products, tat" by people in this website by year, and whether "Gene Products, tat" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 1 | 3 | 4 |
| 1996 | 2 | 0 | 2 |
| 1997 | 2 | 1 | 3 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 2 | 4 |
| 2001 | 1 | 3 | 4 |
| 2002 | 4 | 1 | 5 |
| 2003 | 3 | 2 | 5 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 0 | 2 |
| 2006 | 5 | 0 | 5 |
| 2007 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gene Products, tat" by people in Profiles.
-
a2d-1 switches the phenotype of synaptic AMPA receptors by physically disrupting heteromeric subunit assembly. Cell Rep. 2021 07 20; 36(3):109396.
-
Cyclin-dependent kinases as therapeutic targets for HIV-1 infection. Expert Opin Ther Targets. 2016 Dec; 20(12):1453-1461.
-
Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology. 2013 Jun 05; 440(2):210-21.
-
Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant. J Acquir Immune Defic Syndr. 2008 Apr 01; 47(4):403-11.
-
Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'. J Acquir Immune Defic Syndr. 2008 Apr 01; 47(4):412-21.
-
A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol. 2007 Apr; 81(7):3414-27.
-
TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol. 2007 May; 14(5):1763-71.
-
The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection. J Infect Dis. 2006 Sep 15; 194(6):760-3.
-
Selective cell uptake of modified Tat peptide-fluorophore conjugates in rat retina in ex vivo and in vivo models. Invest Ophthalmol Vis Sci. 2006 Jun; 47(6):2589-95.
-
TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol. 2006 May 01; 176(9):5471-7.